MedTrace Logo

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2026-04-30

No results posted yet for this study

Summary

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

Conditions

  • Locally Advanced Cervical Cancer

Interventions

BIOLOGICAL

Volrustomig

IV Infusion

OTHER

Placebo

IV Infusion

Sponsors & Collaborators

  • Gynecologic Oncology Group Foundation

    collaborator UNKNOWN

  • European Network for Gynaecological Oncological Trial Groups

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-22
Primary Completion
2027-11-26
Completion
2030-09-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Brazil
  • Canada
  • China
  • Denmark
  • Germany
  • India
  • Italy
  • Japan
  • Mexico
  • Norway
  • Peru
  • Poland
  • Puerto Rico
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06079671 on ClinicalTrials.gov